Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4518-4521
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4518
From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies
Mo-Wei Kong, Yang Yu, Ying Wan, Yu Gao, Chun-Xiang Zhang
Mo-Wei Kong, Yang Yu, Department of Cardiology, Southwest Medical University, Luzhou 646000, Sichuan Province, China
Ying Wan, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, Sichuan Province, China
Yu Gao, Department of Endocrinology, The Affiliated Hospital of Chengde Medical College, Chengde 067000, Hebei Province, China
Chun-Xiang Zhang, Department of Pharmacology and Rush University Cardiovascular Research Center, Rush University Medical Center, Luzhou 646000, Sichuan Province, China
Co-first authors: Mo-Wei Kong and Yang Yu.
Author contributions: Kong MW and Yu Y wrote the manuscript; Designation of Kong MW and Yu Y as joint first authors are based on three main reasons; Kong MW and Yu Y contributed efforts of equal substance throughout the research process. Selecting these researchers as joint first authors acknowledge and respect this equal contribution, while recognizing the spirit of teamwork and collaboration of this study; Zhang CX provided crucial suggestions and guidance for the writing; Wan Y and Gao Y reviewed and revised the manuscript; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. U23A20398 and No. 82030007; and Sichuan Science and Technology Program, No. 2022YFS0578.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Xiang Zhang, MD, Dean, Professor, Department of Pharmacology and Rush University Cardiovascular Research Center, Rush University Medical Center, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. zhangchx999@163.com
Received: July 27, 2024
Revised: September 17, 2024
Accepted: October 9, 2024
Published online: November 15, 2024
Processing time: 90 Days and 5.4 Hours
Core Tip

Core Tip: This article reviews the integration of novel combined therapies and biomarker identification in hepatocellular carcinoma (HCC) management. The studies by Zhang et al and Li et al explore the efficaciousness of a triple therapy involving transarterial chemoembolization, tyrosine kinase inhibitors, and PD-1 inhibitors, and the prognostic value of protein tyrosine phosphatase non-receptor II (PTPN2), respectively. These investigations underscore the significance of PTPN2 as a potential therapeutic target and highlight the promise of synergistic treatment strategies in enhancing HCC patient outcomes.